Efficacy and safety of Dimethyl fumarate in comparison with conventional therapy for psoriasis: an Italian real‐world clinical experience.

Patients on DMF had used systemic therapies for psoriasis, including biologics, more frequently than patients under other systemic treatments (73.4% vs. 50.7%, I P i = 0.003). DMF may be the preferred choice for multi-failure psoriasis patients with treatment-emergent side-effects, due to its favourable long-term safety profile. When comparing patients on DMF versus patients under other systemic treatments through cumulative PASI75 up to the first therapy discontinuation, we found, from month 9 onwards, a slightly superior improvement in the DMF group, although without any statistically significant difference (Figure 1). [Extracted from the article]